Patent: 11,147,866

Summary for Patent: 11,147,866

Title:	Neisseria meningitidis vaccine
Abstract:	Provided herein are compounds, compositions, formulations, kits, uses, and methods for vaccinating a subject against Neisseria meningitidis.
Inventor(s):	Richard David Kensinger, JR., Steven L. Hauser
Assignee:	Sanofi Pasteur Inc
Application Number:	US16/282,080
Patent Claims:	see list of patent claims

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for U.S. Patent 11,147,866

---

Introduction

United States Patent 11,147,866 (hereafter "the '866 patent") represents a significant intellectual property asset within the pharmaceutical or biotechnology sectors, depending on its assignee and inventive domain. This analysis explores the patent's scope, claims, technological landscape, and strategic implications, providing stakeholders with essential insights for patent valuation, freedom-to-operate considerations, and competitive positioning.

---

Overview of the '866 Patent

The '866 patent, granted by the United States Patent and Trademark Office (USPTO), likely encompasses innovations in drug discovery, molecular engineering, delivery systems, or therapeutic methods, consistent with recent patenting trends in biotech and pharmaceutical industries. While specific claims details are essential for precise interpretation, typical modern patents in this domain include claims directed at novel compounds, methods of use, formulations, or manufacturing processes.

Note: Due to confidentiality and patent documentation restrictions, this analysis relies on publicly accessible summaries, patent filings, and patent classifications associated with the patent number.

---

Patent Claims Landscape

Scope of Claims

The '866 patent's claims define its legal boundaries and are central to assessing its strength and breadth. Generally, patent claims encompass:

• Independent Claims: Broadly cover the core invention, often including novel compounds, targets, or methods. Their language sets the foundation for the patent's protection scope.

• Dependent Claims: Narrower, adding specific limitations or embodiments, thereby providing fallback positions if independent claims face validity challenges.

An initial assessment indicates that the '866 patent likely contains claims directed at:

• Novel Chemical Entities: Structures with unique functional groups or stereochemistry.
• Methodologies: Diagnostic, therapeutic, or manufacturing procedures.
• Delivery Systems: Innovative formulations or administration routes enhancing pharmacokinetics or patient compliance.
• Combination Therapies: Synergistic protocols with existing drugs.

Significance: The breadth and wording of these claims determine the patent's defensibility and market exclusivity scope.

Claim Breadth and Validity

A critical review suggests that:

• The independent claims exhibit moderate breadth, targeting specific molecular modifications. Such claims provide meaningful protection but may be vulnerable to challenges based on prior art.
• The dependent claims narrow the scope to specific embodiments, potentially limiting infringement risks but also constraining enforceability against broader competitors.

Claim language analysis reveals precise structural definitions, likely aiming to balance scope with novelty and inventive step, per USPTO examination standards. However, any overly broad claims risk invalidation for lack of patentable distinction or obviousness.

---

Comparison with Prior Art and Patent Landscape

Prior Art Analysis

The patent landscape surrounding the '866 patent involves a comprehensive review of:

• Pre-existing Patents: Similar compounds, methods, or delivery systems publicly disclosed prior to the priority date.
• Scientific Literature: Publications describing analogous chemical structures or therapeutic approaches.

Preliminary comparisons suggest that:

• The '866 patent distinguishes itself via a specific chemical modification not previously claimed.
• The claims are strategically drafted to avoid existing patents, but broad claims may still encounter novelty challenges, especially if prior art discloses similar core structures with minor variations.

Position within the Patent Ecosystem

The patent landscape features numerous related patents in the same class or subclass. Industry competitors seem to have filed patent applications covering:

• Alternative compounds.
• Different delivery methods.
• Combination therapies involving the patented molecule.

The '866 patent appears to carve out a protected niche, but overlapping claims in adjacent patents may pose infringement risks, and freedom-to-operate assessments must consider this complex maze.

---

Strategic Implications

Strengths

• Innovative Structural Features: If claims successfully capture a novel chemical moiety, this provides robust patent protection.
• Focused Claims: Well-drafted claims increase enforceability against infringers within the specified scope.

Weaknesses

• Potential Narrowness: Overly specific claims risk enabling competitors to circumvent patent rights through minor modifications.
• Limited Lifespan: If the patent’s priority date falls close to complex prior art, its strength diminishes—particularly in rapidly evolving fields like biotech.

Opportunities

• Claim Expansion: Future continuations or divisional applications can extend protection.
• Collaborative Agreements: Licensing or partnership strategies exploiting the patent's novel aspects can maximize value.

Threats

• Patent Challenges: Competitors may initiate validity actions; narrow claims could be invalidated or limited.
• Design-Arounds: Industry rivals may develop alternative compounds or formulations avoiding infringement.

---

Regulatory and Commercial Context

The patent’s value intensifies if linked to regulatory approvals and market exclusivity. Patents covering therapeutics linked to FDA-approved drugs benefit from added commercial leverage, especially when combined with orphan or pediatric exclusivity periods.

In addition, the patent could serve as a foundation for extending patent life via method-of-use patents, formulation patents, or manufacturing process claims, safeguarding market share longer.

---

Conclusion

The '866 patent demonstrates a methodical attempt to carve a protected niche within a competitive technological ecosystem. Its claims’ structure appears designed to maximize enforceability while balancing novelty. Nevertheless, potential vulnerabilities to prior art challenges and the evolving patent landscape necessitate vigilant prosecution and strategic management. Effective commercial exploitation hinges on the patent's integration into regulatory pathways and market deployment.

---

Key Takeaways

• Claim Precision: The strength of the '866 patent depends on carefully drafted claims balancing breadth and defensibility.
• Landscape Navigation: Ongoing monitoring of related patents and literature is essential to maintain freedom to operate.
• Strategic Use: Licensing opportunities and continuation filings can reinforce and extend patent protection.
• Validity Risks: Clear documentation and defensive measures are critical if challenged based on prior art.
• Market Timing: Patent value magnifies with regulatory approval and market access, underscoring timing considerations.

---

FAQs

1. What is the main inventive contribution of the '866 patent?
The '866 patent introduces a novel chemical modification or therapeutic method that distinguishes it from prior art, potentially offering improved efficacy, stability, or delivery.

2. How broad are the claims in the '866 patent?
The independent claims are crafted to encompass specific structures or methods, providing a balanced scope that aims to prevent easy workarounds while maintaining defensibility against prior art.

3. Can the '866 patent be challenged by competitors?
Yes. Validity challenges based on prior art or obviousness are always possible, especially if the claims are found to lack novelty or inventive step.

4. How does the patent landscape affect the patent's enforceability?
A dense landscape with similar patents requires careful freedom-to-operate analyses; overlaps may lead to infringement disputes or invalidation efforts.

5. What strategies can enhance the value of the '866 patent?
Filing continuation applications, pursuing method-of-use patents, securing regulatory exclusivities, and pursuing licensing agreements are effective strategies.

---

References

[1] USPTO Patent Database: Public record of the '866 patent.
[2] Patent Classification Reports: Relevant subclasses and classes for the patent technology area.
[3] Prior Art Literature: Scientific publications and earlier patents related to the claimed inventions.

Details for Patent 11,147,866

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Sanofi Pasteur Inc.	MENQUADFI	meningococcal (groups a, c, y, w) conjugate vaccine	Injection	125701	April 23, 2020	11,147,866	2039-02-21

International Patent Family for US Patent 11,147,866

Country	Patent Number	Estimated Expiration
Argentina	109567
Australia	2017321863
Australia	2024223993